Risk factors for wet AMD revisited

Article

Age-related macular degeneration (AMD) is a common cause of vision loss worldwide, particularly in industrialized nations, where it is the main cause of blindness among people of 65 and older, explained Paul Mitchell, MD, at the World Ophthalmology Congress.

Age-related macular degeneration (AMD) is a common cause of vision loss worldwide, particularly in industrialized nations, where it is the main cause of blindness among people of 65 and older, explained Paul Mitchell, MD, at the World Ophthalmology Congress.

"Disease subtypes are early AMD, which accounts for around 75% of cases, and late AMD, which is further classified into dry AMD, with an atrophic presentation, and wet AMD," he said. Dr. Mitchell is a retina specialist in Sydney, Australia, and principal investigator of the Blue Mountains Eye Study (BMES). Data obtained in that research were comparable to those from other population-based studies such as the Beaver Dam, Rotterdam and EUREYE.

The neovascular form is most common in late AMD, its ratio of prevalence compared to atrophic being 2:1. In this presentation, vascular endothelial growth factor (VEGF) plays an important role in neovascular processes in the eye, and is the therapeutic target of AMD available treatments.

"Neovascular or wet AMD causes mild visual impairment in its early stages but progresses over time and frequently results in blindness," said Dr. Mitchell. "That's why detection of its major risk factors is key in the prevention of the disease. The natural and more important factor is age, with a significant step in the mid-70's, but genetics and especially smoking follow closely."

Genetics can confer a four-fold higher risk. Current smokers, according to pooled data from the BMES, Rotterdam, and the Beaver Dam studies, have a 300-fold increase in risk for AMD. "In average, smoking may prompt the appearance of AMD in 5 to 10 years in comparison to non-smokers," Dr. Mitchell pointed out. A possible association of cataract surgery with AMD was also found in another sub-study.

A growth of about 50% is expected in the global incidence of wet AMD, as longevity increases. "As this aging population looses independence in all daily activities, it poses a problem for the healthcare system, with increased use of community support services and a greater necessity for nursing home admission," he concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.